Refine
Has Fulltext
- yes (73)
Is part of the Bibliography
- yes (73)
Year of publication
Document Type
- Journal article (59)
- Conference Proceeding (8)
- Preprint (6)
Keywords
- PET (22)
- Positronen-Emissions-Tomografie (21)
- positron emission tomography (15)
- theranostics (9)
- neuroendocrine tumor (8)
- prostate cancer (7)
- SPECT (6)
- 18F-FDG (5)
- PET/CT (5)
- PRRT (5)
- PSMA (5)
- RADS (5)
- SSTR (5)
- CXCR4 (4)
- inflammation (4)
- molecular imaging (4)
- norepinephrine transporter (4)
- prostate-specific membrane antigen (4)
- radioligand therapy (4)
- sympathetic nervous system (4)
- 18F-DCFPyL (3)
- 18F-LMI1195 (3)
- DaTscan (3)
- Prostate Cancer (3)
- ageing (3)
- peptide receptor radionuclide therapy (3)
- somatostatin receptor (3)
- vandetanib (3)
- 11C-HED (2)
- 18F-FDS (2)
- ECG (2)
- Ioflupane (2)
- MIBG (2)
- MRI (2)
- Myokarditis (2)
- PSMA-PET (2)
- PSMA-RADS (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- SSTR-RADS (2)
- Stammzelle (2)
- TKI (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- antidepressant (2)
- cardiomyocytes (2)
- chemokine receptor (2)
- diabetes (2)
- fatty acid (2)
- heart (2)
- heart failure (2)
- hiPSC-CM (2)
- induced pluripotent stem cells (2)
- kidney (2)
- machine learning (2)
- medullary thyroid carcinoma (2)
- molecular medicine (2)
- myocardial sympathetic innervation imaging (2)
- myocarditis (2)
- personalized medicine (2)
- personalized treatment (2)
- precision medicine (2)
- prostate-specific membrane antigen (PSMA) (2)
- reporting and data system (2)
- somatostatin receptor (SSTR) (2)
- stem cell therapy (2)
- tracer (2)
- tumor heterogeneity (2)
- tyrosine kinase inhibitor (2)
- 11C-Hydroxyephedrine (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 123I-mIBG (1)
- 123I-metaiodobenzylguanidine (1)
- 177Lu (1)
- 18F-DCFPL (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 5IA-SPECT (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- 99mTc-DTPA (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AI (1)
- Alzheimer’s disease (1)
- Antidepressants (1)
- C-X-C motif chemokine receptor 4 (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- Cardiovascular diseases (1)
- DCGAN (1)
- DOTATOC (1)
- DYT1 (1)
- Diabetes (1)
- Dystonia (1)
- ECG-gated (1)
- EKG (1)
- FV45 (1)
- GAN (1)
- GCA (1)
- GI (1)
- Ganglia (1)
- Gastrointestinal (1)
- Glomerular filtration (1)
- HFmrEF (1)
- HMDP hydroxymethylene diphosphonate (1)
- Heart failure (1)
- Herz (1)
- Imaging pitfalls (1)
- Journal of Nuclear Cardiology (1)
- MAG3 (1)
- MDD (1)
- MI-RADS (1)
- MPI (1)
- Magnetresonanztomografie (1)
- Medullärer Schilddrüsenkrebs (1)
- Metaiodobenzylguanidine (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- NET (1)
- Neuroendocrine (1)
- Neuroendocrine Tumor (1)
- Nierenfunktionsstörung (1)
- OXPHOS (1)
- Oncology (1)
- P-glycoprotein expression (1)
- PMR (1)
- PROMISE (1)
- PSMA I&T (1)
- PSMA-617 (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-targeted PET (1)
- Pancreas (1)
- Parkinson disease (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Pitfall (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Prostata (1)
- RLT (1)
- ROS (1)
- Radiofluorine (1)
- Radionuclide Therapy (1)
- Radiotracer (1)
- SARS-CoV-2 (1)
- SPECT Scanner (1)
- SPECT/CT (1)
- SSTR-PET (1)
- SUV (1)
- Simvastatin (1)
- Single-Photon-Emissions-Computertomographie (1)
- Sodium-Glucose Cotransporters (SGLTs) (1)
- Standardisierung (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- Technetium Tc 99m Sestamibi Rats (1)
- Tracer (1)
- ZDF rats (1)
- [177Lu]/[90Y]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [68Ga]DOTATOC (1)
- [68Ga]PentixaFor (1)
- [68Ga]Pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- \(^{68}\)Ga (1)
- amyloid-β (Aβ) (1)
- angiotensin II type 1 receptor (1)
- antidepressants (1)
- artificial intelligence (1)
- autonomic nervous system (1)
- benzylguanidine (1)
- biomarkers (1)
- blood flow (1)
- butyrylcholinesterase (1)
- carbamate (1)
- cardiac (1)
- cardiac innervation imaging (1)
- cardiac nerve (1)
- cardiac neurohormonal system (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- cardioprotective potential (1)
- cell biology (1)
- cognitive decline (1)
- combination (1)
- computational biology and bioinformatics (1)
- contractility (1)
- coronary artery disease (1)
- depression (1)
- diabetic cardiomyopathy (1)
- diabetische Kardiomyopathie (1)
- dilated cardiomyopathy with ataxia (1)
- dopamine (1)
- dopamine acetylcholine (1)
- editorial (1)
- ejection fraction (1)
- endocrinology (1)
- endoradiotherapy (1)
- enzyme kinetics (1)
- fibroblast activation protein (1)
- fluorine-18 (1)
- genetics (1)
- giant cell arteritis (1)
- glomerular filtration rate (1)
- heart failure with mid-range ejection fraction (1)
- hematotoxicity (1)
- hydroxyephedrine (1)
- interobserver (1)
- interreader (1)
- left-ventricular function (1)
- mIBG (1)
- magnetic resonance imaging (1)
- major depressive disorder (1)
- matched pair (1)
- mechanisms retention (1)
- medium-sized animals (1)
- meningioma (1)
- metabolism (1)
- mitochondria (1)
- molecular biology (1)
- mouse (1)
- moycardial sympathetic innervation (1)
- myocardial perfusion imaging (1)
- nephrology (1)
- nephrotoxicity (1)
- neuroblastoma (1)
- neuroendocrine neoplasia (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumors (NET) (1)
- neurology (1)
- nicotinic receptors (1)
- nonhuman primates (1)
- nuclear cardiology (1)
- ollimator (1)
- organic cation transporter (1)
- pancreas (1)
- papillary thyroid carcinoma (PTC) (1)
- performance (1)
- peripheral injury (1)
- phaeochromocytoma (1)
- phenethylguanidine (1)
- polymyalgia rheumatica (1)
- post-reconstruction filtering (1)
- quality (1)
- quantification (1)
- radioiodine (1)
- radiotracer (1)
- radiotracer kinetics (1)
- radiotracers (1)
- rats (1)
- renal (1)
- renal failure (1)
- renal function (1)
- renal imaging (1)
- renal scintigraphy (1)
- renin-angiotensin system (1)
- reporting and data systems (1)
- scanner (1)
- second hit (1)
- selpercatinib (1)
- sepsis (1)
- sigma-1 receptor-directed molecular imaging (1)
- single photon emission computed tomography: sympathetic nerve (1)
- skeletal (1)
- small animal SPECT (1)
- small-animal imaging (1)
- solid tumors (1)
- split renal function (1)
- standardization (1)
- standardized reporting (1)
- statin (1)
- stem cells (1)
- stem-cell research (1)
- storage vesicle turnover (1)
- stroke (1)
- structure–activity relationships (1)
- sympathetic nerve (1)
- thyroid carcinoma (TC) (1)
- unilateral ureteral obstruction (1)
- urology (1)
- valsartan (1)
- vasculature (1)
- vasculitis (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (73)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (11)
- Medizinische Klinik und Poliklinik I (11)
- Medizinische Klinik und Poliklinik II (9)
- Institut für Pharmazie und Lebensmittelchemie (6)
- Institut für Anatomie und Zellbiologie (5)
- Institut für Pharmakologie und Toxikologie (3)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (3)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Neurologische Klinik und Poliklinik (2)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (18)
- Johns Hopkins University School of Medicine (5)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (3)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Department of Nuclear Medicine, Kanazawa University (1)
- Hospital Augsburg, Augsburg, Germany (1)
- Johns Hopkins School of Medicine, Baltimore, MD, USA (1)
Whole-Body [\(^{18}\)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
(2021)
The 2-deoxy-d-[\(^{18}\)F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [\(^{18}\)F]FDG PET/CT on change in initially suspected diagnosis in patients at the time of the scan. Thirty-four patients, who had undergone [\(^{18}\)F]FDG PET/CT, were enrolled and the initially suspected diagnosis prior to [18F]FDG PET/CT was compared to the final diagnosis. In addition, a semi-quantitative analysis including vessel wall-to-liver (VLR) and joint-to-liver (JLR) ratios was also conducted. Prior to [\(^{18}\)F]FDG PET/CT, 22/34 (64.7%) of patients did not have an established diagnosis, whereas in 7/34 (20.6%), polymyalgia rheumatica (PMR) was suspected, and in 5/34 (14.7%), giant cell arteritis (GCA) was suspected by the referring rheumatologists. After [\(^{18}\)F]FDG PET/CT, the diagnosis was GCA in 19/34 (55.9%), combined GCA and PMR (GCA + PMR) in 9/34 (26.5%) and PMR in the remaining 6/34 (17.6%). As such, [\(^{18}\)F]FDG PET/CT altered suspected diagnosis in 28/34 (82.4%), including in all unclear cases. VLR of patients whose final diagnosis was GCA tended to be significantly higher when compared to VLR in PMR (GCA, 1.01 ± 0.08 (95%CI, 0.95–1.1) vs. PMR, 0.92 ± 0.1 (95%CI, 0.85–0.99), p = 0.07), but not when compared to PMR + GCA (1.04 ± 0.14 (95%CI, 0.95–1.13), p = 1). JLR of individuals finally diagnosed with PMR (0.94 ± 0.16, (95%CI, 0.83–1.06)), however, was significantly increased relative to JLR in GCA (0.58 ± 0.04 (95%CI, 0.55–0.61)) and GCA + PMR (0.64 ± 0.09 (95%CI, 0.57–0.71); p < 0.0001, respectively). In individuals with a suspected diagnosis of rheumatic disease, an inflammatory-directed [\(^{18}\)F]FDG PET/CT can alter diagnosis in the majority of the cases, particularly in subjects who were referred because of diagnostic uncertainty. Semi-quantitative assessment may be helpful in establishing a final diagnosis of PMR, supporting the notion that a quantitative whole-body read-out may be useful in unclear cases.